Topic summary

Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept

Practice › Dosing & titration dose reduction worked example tirzepatide missed dose semaglutide Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 12, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

s.achebeTL211 Sep 2025#2

The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.

14 likes 11mo

n.torrenceTL3Regular15 Sep 2025#3

br.wikstrom, post #1: Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept I have read the maintained page on this and I still have a gap, so I am asking rather than guessing. Context: semaglutide, 9 weeks in, currently at a dose I reached by the standard four-week steps.… Go to post

Post #2 is right about the mechanism and I think understates the practical bit.

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

Worth checking against a second source before it gets quoted onward.

29 likes in reply to #1 10mo

e.ferrariTL2 Solution27 Sep 2025#6

s.silva, post #5: Adding the measurement that post #2 says would settle it. There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine". This is where my knowledge stops and I would rather mark the edge… Go to post

Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.

I am describing what is, rather than arguing for what should be.

20 likes in reply to #5 10mo

d.nwosuTL210 Oct 2025#10

Knowlton, post #7: The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence. Go to post

Saving this. It is the version I will quote when the question comes round again.

28 likes in reply to #7 10mo

s.ivaturiTL213 Oct 2025#11

Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.

I would put this at better than even and not much better.

11 likes 9mo

Read the full topic (12 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Where the four-week escalation interval comes from, and what it is not Practice › Dosing & titration missed dose semaglutide tirzepatide titration Solved On the subject in the title: Where the four-week escalation interval comes from, and what it is not Working notes rather than a conclusion. Working notes on four-week escalation interval rather than a…	+56	60	21k	2y
How the published trials escalated, tabulated side by side Practice › Dosing & titration worked example semaglutide titration dose reduction Solved Closed The question in the title: How the published trials escalated, tabulated side by side I will give what I have already checked below so nobody repeats it. Something about published trials escalated does not…	+4	8	4.2k	5mo
Restarting after a long gap: what the labelling implies Practice › Dosing & titration dose reduction semaglutide titration missed dose Posting this under the heading it deserves: Restarting after a long gap: what the labelling implies Everything below is what sits behind that. I have read the maintained page on this and I still have a gap,…	+41	46	11k	15h
[2026 update] Dose numbers across compounds are not on the same scale Practice › Dosing & titration dose reduction worked example semaglutide titration On the subject in the title: Dose numbers across compounds are not on the same scale Working notes rather than a conclusion. A narrow question about Dose numbers across compounds, deliberately narrow, because…	+14	18	1.2k	13mo
Reaching a dose and staying there for a year: a longitudinal note — does this still hold? Practice › Dosing & titration missed dose tirzepatide dose reduction titration Solved Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…	+35	39	547	11mo

Related topics — sharing the tags dose reduction, worked example, tirzepatide

Topic	Participants	Replies	Views	Activity
Titles that describe the question, not the situation — what changed since Start Here › How to Ask beginner friendly site feedback worked example guidelines Posting this under the heading it deserves: Titles that describe the question, not the situation — what changed since Everything below is what sits behind that. What changes if the standard account of Titles…	+29	33	29k	10mo
What a confidence interval means, from scratch Research Methods › Statistics number needed to treat confounding worked example heterogeneity What a confidence interval means, from scratch — that is the question, and I have not found it answered plainly anywhere I have looked. Asking about confidence interval directly, because I have read four…		2	2.6k	2mo
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Pharmacology › Receptor biology retatrutide amylin analogues semaglutide Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. A narrow question about…	+57	63	1k	6mo
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Devices › Syringes & needles syringe units subcutaneous injection needle gauge & length dead volume Wiki 0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters — setting out what I have, and where I think it stops being reliable. A follow-up question about 0.3 ml versus 0.5 ml that I did not know to ask…	+104	114	6k	6d
Measurement error in home scales, with a worked standard deviation Research Methods › Statistics effect size heterogeneity number needed to treat confounding Solved Wiki Measurement error in home scales, with a worked standard deviation Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of measurement error…	+26	31	4.3k	4mo